Prescription drug · BLA
Susvimo (ranibizumab) NDC 50242-078
Ranibizumab 100 mg/mL · Injection, Solution · Intravitreal · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-078-12 | 50242007812 | 1 VIAL in 1 CARTON (50242-078-12) / 1 mL in 1 VIALMarketed from Oct 22, 2021 | |
| 50242-078-55 | 50242007855 | 1 VIAL in 1 CARTON (50242-078-55) / 1 mL in 1 VIALMarketed from Oct 22, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Susvimo
- Generic name (nonproprietary)
- ranibizumab
- Active ingredients
- Ranibizumab — 100 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravitreal
- Labeler
- Genentech, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761197
- Marketing start
- Listing expires
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)
- Identifiers
- Product ID 50242-078_2850382e-4e4f-4005-a047-33fc758bafefSPL ID 2850382e-4e4f-4005-a047-33fc758bafefSPL set ID 9c6d9e2a-9a77-4d11-b692-de87cfde3444RxCUI 2584857, 2584863UNII ZL1R02VT79
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J2778 — Injection, ranibizumab, 0.1 mg
Billing unit: 0.1 mg. Units on the claim = dose given ÷ 0.1 mg.
Ranibizumab biosimilars and the ranibizumab implant have their own HCPCS codes.
- Administration
Intravitreal injection procedure (CPT 67028)
The intravitreal injection is reported as a separate procedure from the drug supplied.
- NDC on a medical claim
N450242007812followed by a unit qualifier and the quantityPackage 50242-0078-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ). 1.1 Neovascular (wet) Age-related Macular Degeneration (AMD) SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (we…
Excerpt only. Read the full label for complete information.